Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ISC 2018: DEFUSE 3 Results Bring DAWN Of New Stroke Guidelines

Executive Summary

Results of the DEFUSE 3 trial presented at the International Stroke Conference in Los Angeles, along with the previously announced DAWN trial results, support a new recommendation in the American Heart Association/American Stroke Association guidelines on early management of acute ischemic stroke, extending the viable treatment window from six hours to 24 hours in some patients. The change could drive thrombectomy uptake and an aspiration-first approach.

You may also be interested in...



Stryker Pushes For Changes To Stroke Care After DAWN

Stryker's Trevo Retriever is the first stent retriever approved by US FDA as a front-line treatment for patients experiencing acute ischemic stroke up to 24 hours from symptom onset, matching the time window recommended in the latest professional treatment guidelines. Now, the company is trying to help the stroke-care system in the US catch up to the science.

Global Approvals Analysis: Eight Brain Device Approvals Mark Neurotech November

Medtech Insight's Approvals Tracker reports 22 medical device approvals from outside the United States in November, including 12 CE marks from Europe, plus approvals from Taiwan, Singapore, Japan, India, Canada, Australia and Argentina.

Stryker's DAWN Thrombectomy Trial Could Also Help Medtronic And Penumbra

Results of the DAWN trial show that endovascular thrombectomy with Stryker's Trevo produces better outcomes than medication alone when used in certain patients who experienced an ischemic stroke. The results could provide a boost to Stryker as well as Stryker's competitors in the mechanical thrombectomy market, including Medtronic, Penumbra.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT122129

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel